Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in children with uncontrolled persistent asthma
NCT02948959Phase 3Completed
- Sponsor
- Sanofi
- Start
- Apr 2017
- Primary completion
- Aug 2020
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing Dupilumab Arm with Placebo Arm (2 arms). Primary endpoint: Annualized Rate of Severe Exacerbation Events at 52 weeks. Started Apr 2017; status: completed.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02948959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02948959.